Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EF-2 Peptide Vaccine
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
EF-2 Peptide Vaccine is an immunostimulant drug initially developed by the National Cancer Institute (NCI) for the treatment of neoplasms. It is a peptide-based vaccine that utilizes peptides derived from eukaryotic elongation factor 2 (eEF2). These eEF2-derived peptides are designed to bind to human leukocyte antigen (HLA) molecules, specifically HLA-A*0201, on the surface of cancer cells. This presentation of the peptide by HLA molecules is intended to stimulate an immune response against the cancer cells. The drug has been investigated for its potential in treating various cancers, including recurrent pediatric sarcomas.
- Other names
- eEF2-derived peptideseEF-2-derived peptideseEF 2-derived peptides
02
Targets
pMHC-I (Peptide–MHC class I complex)EEF2 (Eukaryotic elongation factor 2)MHC I (MHC class I})
Beyond the preview
Go deeper on EF-2 Peptide Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EF-2 Peptide Vaccine.